auanet.org/guidelines-and-q...
Not surprising. I think they should recommend adjuvant ADT at a PSA≥0.35 instead of ≥0.7 because I think patients are hoping for curative SRT and not just equivalent survival.
prostatecancer.news/2022/05...
Also, they did not incorporate the results of the EMBARK and PRESTO trials that proved the benefits of adding Xtandi and Erleada, respectively, for a non-metastatic recurrence when the PSADT is rapid.